Compare Medpace Holdings Inc (MEDP) vs Toro Company (The) Common Stock (TTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Toro Company (The) Common Stock — how do they compare? Medpace Holdings Inc trades at $616.98 (market cap $17.21B), while Toro Company (The) Common Stock trades at $98.27 (market cap $9.30B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Toro Company (The) Common Stock pays a 1.59% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Toro Company (The) Common Stock for 0 Days on average.
| MEDP | TTC | |
|---|---|---|
Market Cap | $17.21B | $9.30B |
Volume | 311,245 | 420,909 |
Sector | Health | Industrials |
52-Week High | $630.19 | $101.76 |
52-Week Low | $393.42 | $67.99 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $16.83B | $10.20B |
Dividend Yield | — | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $609.89, down 1.64% today, with a bullish technical signal and strong support near $606. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue grew to $2.53B in 2025, with a net income margin of 17.67%. Recent news highlights CEO stock sales and institutional position adjustments.
Outlook remains positive with a consensus price target of $620.44, offering modest upside. Key risks include high valuation multiples and insider selling. Earnings growth and sector demand are primary catalysts, but investor caution is warranted given elevated P/E and P/B ratios.
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Toro Company (The) Common Stock
The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →
